These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 14514981)

  • 1. Epoetin alfa and intravenous iron sucrose to treat severe anemia in a patient with chronic radiation enteropathy: a case report.
    Séronie-Vivien S; Mourey L; Tohfe M; Bugat R
    Med Oncol; 2003; 20(3):301-6. PubMed ID: 14514981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy.
    Henry DH; Dahl NV; Auerbach M; Tchekmedyian S; Laufman LR
    Oncologist; 2007 Feb; 12(2):231-42. PubMed ID: 17296819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data.
    Pollak VE; Lorch JA; Shukla R; Satwah S
    BMC Nephrol; 2009 Feb; 10():6. PubMed ID: 19245700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients.
    Schiesser D; Binet I; Tsinalis D; Dickenmann M; Keusch G; Schmidli M; Ambühl PM; Lüthi L; Wüthrich RP
    Nephrol Dial Transplant; 2006 Oct; 21(10):2841-5. PubMed ID: 16891647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: an open-label, non randomized, pilot study.
    Santini D; Vincenzi B; La Cesa A; Virzi V; Navajas F; Malafarina V; Dicuonzo G; Cassandro R; Esposito V; Montesarchio V; Groeger AM; Tonini G
    Anticancer Res; 2005; 25(1B):669-74. PubMed ID: 15816644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of epoetin alfa administered every 2 weeks to maintain hemoglobin and quality of life in anemic HIV-infected patients.
    Levine AM; Salvato P; Leitz GJ;
    AIDS Res Hum Retroviruses; 2008 Feb; 24(2):131-9. PubMed ID: 18284320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron sucrose with and without recombinant erythropoietin for the treatment of severe postpartum anemia: a prospective, randomized, open-label study.
    Krafft A; Breymann C
    J Obstet Gynaecol Res; 2011 Feb; 37(2):119-24. PubMed ID: 21159035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.
    Krivoshiev S; Wizemann V; Czekalski S; Schiller A; Pljesa S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A;
    Adv Ther; 2010 Feb; 27(2):105-17. PubMed ID: 20369312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
    Patton J; Kuzur M; Liggett W; Miranda F; Varsos H; Porter L
    Oncologist; 2004; 9(1):90-6. PubMed ID: 14755018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly.
    Cartenì G; Giannetta L; Ucci G; De Signoribus G; Vecchione A; Pinotti G; Puglisi F; Contillo A; Pezzella G; Orecchia S; Beccaglia P;
    Support Care Cancer; 2007 Sep; 15(9):1057-66. PubMed ID: 17431689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current recommendations for the treatment of iron deficiency anemia].
    Schaefer RM; Huch R; Krafft A;
    Rev Med Suisse; 2007 Apr; 3(105):874-80. PubMed ID: 17514929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood conservation in the critically ill.
    Thomas J; Martinez A
    Am J Health Syst Pharm; 2007 Aug; 64(16 Suppl 11):S11-8. PubMed ID: 17687066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-weekly epoetin alfa improves quality of life and increases hemoglobin in anemic HIV+ patients.
    Saag MS; Bowers P; Leitz GJ; Levine AM;
    AIDS Res Hum Retroviruses; 2004 Oct; 20(10):1037-45. PubMed ID: 15587490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Guidelines for the treatment of anemia in chronic renal failure].
    Triolo G;
    G Ital Nefrol; 2003; 20 Suppl 24():S61-82. PubMed ID: 14666504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma carnitine profile during chronic renal anemia treatment with recombinant human erythropoietin.
    Debska-Slizień A; Owczarzak A; Kunicka D; Lysiak-Szydłowska W; Rutkowski B
    Int J Artif Organs; 2003 Jan; 26(1):33-8. PubMed ID: 12602467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Impact of anemia correction on the production of the circulating morphogenetic protein α-Klotho in patients with Stages 3B-4 chronic kidney disease: A new direction of cardionephroprotection].
    Milovanov YS; Mukhin NA; Kozlovskaya LV; Milovanova SY; Markina MM
    Ter Arkh; 2016; 88(6):21-25. PubMed ID: 27296257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of darbepoetin-alfa in combination with intravenous iron sucrose in patients with inflammatory bowel disease and refractory anaemia: a pilot study.
    Koutroubakis IE; Karmiris K; Makreas S; Xidakis C; Niniraki M; Kouroumalis EA
    Eur J Gastroenterol Hepatol; 2006 Apr; 18(4):421-5. PubMed ID: 16538115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N; Sriuranpong V; Suwanrusme H
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.